Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Trial Approval, Medtronic Aims For Symplicity RF Catheter Launch In 2014

This article was originally published in The Gray Sheet

Executive Summary

With conditional FDA approval for its pivotal trial in hand, Medtronic says it is on track to launch its Symplicity renal nerve ablation catheter system for drug-resistant hypertension in the U.S. in 2014.

You may also be interested in...



Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS

The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.

Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS

The device is one of the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.

St. Jude Plans Trial To Study Renal Denervation Outcomes

Landmark trial will evaluate whether reductions in blood pressure caused by renal denervation translate to clinical improvements in patients with hard-to-treat hypertension.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel